Celltrion's anti cancer drugs hold 90% market share in C.America

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries.

The company’s biosimilar drug Truxima, a version of Roche’s blood cancer treatment Rituxan, has held over 90% market share in Costa Rica since its 2019 launch and has been supplied through national tenders for six consecutive years.

Herzuma, a biosimilar of Roche’s breast and gastric cancer therapy Herceptin, entered the Costa Rican market in 2021.

In Ecuador, Truxima and Herzuma have maintained a combined market share of 90%, while in the Dominican Republic, the two drugs together account for nearly 80% of prescriptions, according to the company.

Celltrion’s autoimmune disease treatment Remsima, a biosimilar to Janssen's Remicade, also achieved over 90% market share in the Dominican Republic and Panama.

The company plans to launch its metastatic colorectal cancer treatment Vegzelma in Ecuador this month as part of its strategy to expand across the region.

Celltrion is also set to introduce more autoimmune therapies, including the subcutaneous of Remsima and Yuflyma, as it aims to strengthen its presence in the biosimilar market.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com